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Objective: To investigate the expression and regulation of defensins in the peritoneal cavity of peritoneal dialysis (PD) patients.
Design: The presence of defensins in the peritoneal cavity was assessed using reverse transcription polymerase chain reaction (RT-PCR). In vivo defensin expression was analyzed in human peritoneal membrane biopsies and in peritoneal cavity leukocytes isolated from spent dialysate. Defensin KEY WORDS: Defensins; peritoneum; mesothelial cells; peritonitis.
T he incidence of acute peritonitis in patients on peritoneal dialysis (PD) is low, typically averaging once per 1500 or more exchanges, suggesting that the intrinsic peritoneal immune defenses are extremely effective (1, 2) . However, peritonitis remains the leading cause of technique failure, is a key contributor to the progressive damage and fibrosis of the peritoneal membrane, and is a major cause of morbidity and mortality (3, 4) .
The intrinsic defense of the peritoneal cavity relies upon multiple mechanisms, including resident leukocytes (mainly macrophages), antibody, complement, and opsonins (2, 5, 6) . During inflammatory episodes, these mechanisms are augmented by the release of soluble proinflammatory factors such as tumor necrosis factor alpha (TNFa), prostaglandins, and leukotrienes such as interleukin-8, as well as by an influx of inflammatory cells (mainly neutrophils) from the blood (1) .
Potential additional components of this complex defense system are endogenous antimicrobial peptides known as defensins (7, 8) . Mammalian a-and b-defensins constitute a family of peptides with broad activity against bacteria, mycobacteria, fungi, and viruses (7, (9) (10) (11) . They are thought to destroy microorganisms by directly interacting with target cell membranes, forming multimeric pores (11, 12) . There are six known human a-defensins, four of which are contained in neutrophil secretory granules and are termed human neutrophil peptides (HNP) 1-4 (9,13). The remaining two are secreted from Paneth cells into the gastrointestinal tract (14) . The b-defensins are expressed at barrier epithelium and are more potent and selective than a-defensins, killing mainly gramnegative bacteria and yeast (10, 15, 16) . b-Defensins are classified into two subgroups (17) . The first group includes human b-defensin-1 (hbD-1), initially isolated from hemodialysate of humans with end-stage renal failure (18) . It is also expressed at a number of epithelial sites, including the kidney, pancreas, salivary gland, lung, urogenital tract, placenta, and mammary gland (15, (19) (20) (21) . Human b-defensin-2 (hbD-2) belongs to the second group and has been identified in keratinocytes (16) and lung (22, 23) . Unlike hbD-1, whose expression is constitutive, hbD-2 expression is induced by inflammatory stimuli, such as TNFa (16, (24) (25) (26) .
We speculated that defensins may be expressed and contribute to the defense of the peritoneal cavity in patients on PD. In this report we present evidence for in vivo and in vitro expression of a-and b-defensins in the peritoneal cavity, and show that human peritoneal mesothelial cells (HPMC) express hbD-2 that is regulated in these cells by TNFa and epidermal growth factor (EGF).
MATERIALS AND METHODS MATERIALS AND METHODS MATERIALS AND METHODS MATERIALS AND METHODS MATERIALS AND METHODS
All patients involved in this work gave written consent for their participation. Human peritoneal mesothelial cells were isolated from discarded peritoneal dialysate and cultured according to our published method (27) . Patients with current or recent peritonitis were not used as a source. Briefly, spent dialysis fluid was collected and cellular components isolated using low speed (200g) Nonadherent material was removed the next day by two brief washes with HBSS and the adherent population incubated at 37°C, in 5% CO 2 , in fresh culture medium. The resulting cells proliferated to form a monolayer with features typical of cultured HPMC, uniformly positive for cytokeratins 8 and 18, and negative for macrophage and other leukocyte markers, as we reported previously (27) .
REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR) ANALYSIS
Messenger RNA-specific oligonucleotide primers were designed from published genomic sequences (28) such that the recognition sites of the upstream and downstream primers resided in separate exons. Firststrand cDNA synthesis was performed as per manufacturer's instructions (Cat#A3500; Promega Corp., Madison, Wisconsin, U.S.A.). This cDNA was then used in "hot start" PCR reactions using Amplitaq Gold (Perkin Elmer, Norwalk, Connecticut, U.S.A.) according to the supplier's protocol. PCR was performed for 23 cycles for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and actin, and for 30 -35 cycles for other primer pairs (listed in Table 1 ), such that all products could be assayed in the exponential phase of the amplification curve in a thermal cycler (Corbett Research, Melbourne, Victoria, Australia). After an initial step at 95°C for 9 minutes to activate the polymerase, each cycle consisted of 1 minute of denaturation at 94°C, 1 minute of annealing at 62°C, PDI SEPTEMBER 2001 -VOL. 21, NO. 5 DEFENSINS IN THE PERITONEAL CAVITY and 1 minute of extension at 72°C. This was followed by an additional extension step at 72°C for 1 minute.
To eliminate the possibility of false-positive products, control reactions were carried out in parallel using non-reverse transcribed RNA, and on reaction mixtures in which the target RNA was omitted. Amplification products were resolved by electrophoresis on a 2% (w/v) agarose gel (Progen, Darra, Queensland, Australia) and poststained with SYBRGold (Molecular Probes, Eugene, Oregon, U.S.A.). Fluorescent PCR products were then visualized using a FluorImager SF (Molecular Dynamics, Sunnyvale, California, U.S.A.). Oligonucleotide primer sequences and the expected PCR product sizes are listed in Table 1 .
NORTHERN BLOT ANALYSIS
Aliquots of total RNA (20 mg) were electrophoresed through a 1.0% (w/v) agarose gel containing 2.2 mol/L formaldehyde. RNA was transferred onto Hybond-N + (Amersham Co., Arlington Heights, Illinois, U.S.A.) nylon membranes by capillary blotting in 10XSSC (1XSSC is 0.15 mol/L NaCl and 0.015 mol/L sodium citrate, pH 7.0.) (30) and immobilized by ultraviolet cross-linking. The blots were prehybridized in a solution containing l mol/L NaCl, 1% (w/v) SDS, 10% (w/v) dextran sulfate (Progen), 50% (v/v) formamide (ICN Biomedicals), and 100 mg/mL heat-denatured herring sperm DNA (Roche Diagnostics, Castle Hill, New South Wales, Australia), at 42°C for 6 hours. Hybridization was performed in the same solution additionally containing a heat-denatured 269-bp [a-32 P]dATPlabeled cDNA probe for hbD-2. The probe was made using a gel-purified PCR product of hbD-2 that was [a-32 P]dATP-labeled using the GIGA prime random labeling kit (GeneWorks). The blots were washed in 2XSSC and 0.1% (w/v) SDS, once at 42°C and once at 55°C, for 30 minutes each, with a final high stringency wash in 0.1XSSC and 0.1% (w/v) SDS at 55°C for 30 minutes. To allow normalization of mRNA signals, the same filters were stripped using boiling stripping solution [0.1XSSC and 0.1% (w/v) SDS] and reprobed with a 417-bp [a-32 P]dATP-labeled PCR-generated DNA fragment of the housekeeping gene GAPDH. The same hybridization and washing procedures were used as described above. Signals were analyzed using the PhosphorImager SF and quantified using ImageQuant software (Molecular Dynamics).
S E Q U E N C I N G
The hbD-2 PCR product was sequenced using the Qiagen dye terminator protocol (Qiagen Pty Ltd, Clifton Hill, Victoria, Australia). The obtained sequences were then aligned with the published sequences of hbD-1 and hbD-2 using the Clustal X multiple sequence alignment program (31) .
CYTOKINE TREATMENT OF HPMC
Preliminary experiments were conducted to assess the effect of culture conditions on the basal level of hbD-2 mRNA expression. HPMC at second passage were cultured to confluence in Biorich medium in 25-cm 2 tissue culture flasks, as described above, after which the medium was replaced with serum-depleted Biorich culture medium for 24 or 48 hours. Control cells were maintained in Biorich culture medium containing 5% (v/v) FCS for the equivalent duration of the experiment. Cellular RNA was extracted with RNAzol B and the basal level of hbD-2 mRNA assessed using Northern blot analysis.
To assess the effect of TNFa on basal hbD-2 mRNA expression in HPMC, fresh Biorich culture medium, either replete with or depleted of serum, was added to confluent 25-cm 2 flasks of HPMC 24 hours prior to the addition of TNFa. Subsequently, 2 ng/mL TNFa (R & D Systems, Minneapolis, Minnesota, U.S.A.) in serum-depleted Biorich culture medium was added 
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GAPDH = glyceraldehyde-3-phosphate dehydrogenase. a The actin probe was obtained from a previously published sequence (29) . to the cells for a further 24 hours. The resulting RNA isolated from these cells was analyzed as described above.
GROWTH FACTOR TREATMENT OF HPMC
Confluent second-passage HPMC in six-well culture plates were maintained in Biorich culture medium containing 10 ng/mL EGF (Becton Dickinson) for 5 days until a change in cellular morphology to a fibroblastic phenotype was noted, as described (27) . Control cells were cultured for an equal duration in Biorich culture medium in the absence of EGF. Following extraction of total RNA with RNAzol B, hbD-2 mRNA expression was assessed by semiquantitative RT-PCR, as described above.
R E S U L T S R E S U L T S R E S U L T S R E S U L T S R E S U L T S DEFENSINS ARE EXPRESSED IN THE PERITONEAL CAVITY
RNA was prepared from total cellular material recovered from peritoneal dialysate, and subjected to RT-PCR analysis with oligonucleotide primer pairs specific for the conserved region of the human a-defensin, HNP-3, and spanning the intron-exon boundaries of the two human b-defensins, hbD-1 and hbD-2 (Table 1) . Results show the presence of HNP-3, hbD-1, and hbD-2 in cellular material isolated from peritoneal effluent. Of all defensins examined, the mRNA for hbD-2 was the most consistently expressed in these samples [ Figure 1(a) ].
The most likely source of the HNP-3 mRNA was peritoneal leukocytes, and a potential source of the two b-defensins is peritoneal mesothelial cells shed into the peritoneal cavity. In order to test this possibility, RT-PCR was conducted with oligonucleotide primers specific for HNP-3, hbD-1, and hbD-2 on RNA isolated from peritoneal membrane biopsies. Messenger RNA for hbD-2 was detected in 7 of 8 individual peritoneal membrane samples analyzed [ Figure 1(b) ]. Additionally, mRNA corresponding to HNP-3 was also detected in biopsy material, but hbD-1 mRNA was not detected (data not shown).
We speculated that intravascular leukocytes within the biopsy material were the source of the HNP-3 messenger RNA, and that the mesothelial cells lining the peritoneal membrane were the source of the hbD-2 mRNA. In order to test the latter possibility, we studied cultured HPMC derived from patients on PD. The hbD-2 transcript was detected in cultured HPMC and variability in expression between different individuals was noted (Figure 2) . Conversely, HNP-3 and hbD-1 transcripts were consistently not detected in any HPMC cultures (data not shown).
We confirmed the identity of hbD-2 by Southern blot analysis, using an internal oligonucleotide primer specific for the hbD-2 amplicon (data not shown) and by sequencing the hbD-2 PCR product (Figure 3) . Greater than 99% homology to the published sequence was observed for the hbD-2 PCR product produced by HPMC isolated from two patients (Figure 3) . Interestingly, in both patients, a base change from T to C was noted. This did not result in a change in the 
CYTOKINES MODULATE THE EXPRESSION OF b2-DEFENSIN BY HPMC
Investigations were carried out to assess the potential response of HPMC hbD-2 to the inflammatory cytokine TNFa. Northern blot analysis was used to quantify the changes in hbD-2 expression in response to TNFa, relative to the housekeeping gene GAPDH. Preliminary experiments to assess the effect of culture conditions on the basal levels of hbD-2 were conducted on HPMC derived from 4 different individuals, and showed that the level of hbD-2 mRNA expression was maximal in the presence of FCS. Conversely, following a further 24 hours' culture in serumdeprived conditions, levels decreased fourfold, and at 48 hours were considerably lower or not detectable. Representative data for these experiments are presented in Figure 4 .
Next, HPMC at second passage were precultured in the presence of serum or under serum-depleted conditions for 24 hours. Cultures were then treated with 2 ng/mL TNFa for 24 hours in serum-free media. HPMC from 8 individuals were analyzed; representative Northern blots from 3 patients illustrate the variability between individuals in response to TNFa ( Figure 5 ). Patient A, in the presence of serum, dem- onstrated hbD-2 message in the absence of stimulation, but there was no induction with TNFa treatment. For the same patient, serum-depleted conditions reduced the basal level of hbD-2 mRNA 2.3-fold and, similarly, no increase in hbD-2 expression with TNFa stimulation was observed. In contrast, Patient B clearly showed a strong induction in the expression of hbD-2 mRNA (3.5-fold) in response to TNFa compared with the control, but in serum-deprived conditions, there was no induction of hbD-2 mRNA with TNFa stimulation. Patient C showed a response similar to but weaker than that of Patient B, with a 1.5-fold induction of hbD-2 mRNA in response to TNFa in the presence of serum and, unlike Patients A and B, also showed a small increase (1.4-fold) in hbD-2 mRNA expression in the presence of TNFa in serum-deprived conditions. These results suggest that hbD-2 mRNA levels increase in HPMC in response to TNFa, although there is patient variability, and prolonged serum-depleted conditions attenuate this response. We next examined the effect of EGF on the expression of hbD-2 mRNA in cultured HPMC. The cells were treated with EGF (10 ng/mL) for 5 days to induce development of a fibroblastoid phenotype. RT-PCR analysis indicated individual variation in the basal levels of expression of hbD-2 mRNA in untreated control cells, consistent with the previously observed variability in hbD-2 mRNA expression between patients ( Figure 6 ). However, consistently reduced levels of hbD-2 mRNA expression were observed in the EGF-stimulated fibroblastoid HPMC ( Figure 6 ).
This report provides evidence for the mRNA expression of genes encoding defensin antimicrobial peptides within the peritoneal cavity of patients on PD. The expression of mRNA for a-defensin HNP-3 and the two human b-defensins, hbD-1 and hbD-2, was shown in peritoneal cell isolates. The expression of HNP-3 is likely attributable to leukocytes in the peritoneal dialysate (32, 33) , and thus it was not surprising to find increased levels of HNP-3 mRNA in the patient with peritonitis, consistent with the marked influx of neutrophils into the peritoneal cavity. The expression of human b-defensins in the peritoneal cavity, and in particular, expression of hbD-2 by peritoneal mesothelial cells, has not previously been reported. The detection of hbD-1 mRNA in the peritoneal cellular isolates may be accounted for by the resident macrophages; a recent report identified the equivalent of human b1-defensin in bovine alveolar macrophages (34) . The source of the b2-defensin appears to be peritoneal mesothelial cells. The hbD-2 mRNA transcript was detected in peritoneal membrane biopsies, which are known to be enriched with mesothelial cells but also contain leukocytes, vascular endothelial cells, and fibroblasts. In addition, hbD-2 mRNA was persistently expressed in cultured HPMC, which we have previously shown to consist principally of mesothelial cells and which are negative for markers of leukocytes, macrophages, vascular endothelial cells, and fibroblasts (27) .
Elevated plasma levels of b-defensins have been identified in patients with bacterial pneumonia (22) . Furthermore, local b-defensin concentrations are increased at sites of injury and trauma or upon exposure to microbial substances (26, 35, 36) . The hbD-2 mRNA expression by HPMC was upregulated in response to the inflammatory cytokine TNFa, and was attenuated in the absence of serum. These results suggest that mesothelial cells participate in the innate defense of the peritoneum and respond to inflammatory stimuli with upregulation of b-defensin expression. The reduction of hbD-2 mRNA expression under serum-deprived conditions suggests that repeated exposure of the peritoneal mesothelium to large volumes of dialysate might compromise this defense.
It was interesting to observe considerable variability in the levels of basal and induced hbD-2 mRNA expression, particularly as the incidence of peritonitis differs markedly between individuals on PD. This, in addition to loss of mesothelial cells with time on PD and the associated decrease in net hbD-2 expression, might also contribute to the development of peritonitis in such patients.
Epidermal growth factor and the closely related heparin binding EGF are mitogenic for mesothelial cells, and EGF has been shown to alter the phenotype of mesothelial cells to fibroblastoids (27) . In doing so, we have suggested that these growth factors aid wound repair in the peritoneal membrane (27, 37) . The EGF treatment of cultured HPMC consistently downregulated hbD-2 mRNA expression. The regulation of defensin expression by growth factors has not previously been reported. One possible explanation for this observation is that the initial repair of the mesothelial cell layer aims primarily to restore an intact membrane rather than the functional aspects of that membrane. A number of other repair cytokines have been identified in the peritoneal cavity (e.g., transforming growth factor beta and platelet-derived growth factor), and it will be of interest to determine whether these have similar effects on hbD-2 expression.
In conclusion, we have shown the expression of a-and b-defensin genes in the peritoneal cavity, and have made the novel observation that hbD-2 is expressed by peritoneal mesothelial cells. This is further evidence for the direct involvement of mesothelial cells in innate defense mechanisms in the peritoneal cavity. We anticipate that future studies will further reveal important information about the peritoneal immune system, and potentially lead to novel therapeutic advances. The authors gratefully acknowledge the assistance of the nursing staff of the Royal Adelaide Hospital Renal Unit in obtaining patient specimens, Dr. David Watson for supplying peritoneal biopsies, and the patients who consented to supply the material that made this work possible.
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